Last reviewed · How we verify
Acid inhibitors
Acid inhibitors reduce gastric acid secretion to treat acid-related gastrointestinal disorders.
Acid inhibitors reduce gastric acid secretion to treat acid-related gastrointestinal disorders. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.
At a glance
| Generic name | Acid inhibitors |
|---|---|
| Sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
| Drug class | Acid inhibitor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
This drug class works by suppressing the production or neutralization of stomach acid, thereby reducing damage to the gastric mucosa and esophagus. Acid inhibitors are commonly used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and other acid-related conditions. The specific mechanism may involve H2-receptor antagonism, proton pump inhibition, or antacid activity depending on the formulation.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Constipation
- Nausea
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acid inhibitors CI brief — competitive landscape report
- Acid inhibitors updates RSS · CI watch RSS
- Xiyuan Hospital of China Academy of Chinese Medical Sciences portfolio CI